Xi Xu

发表

Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.

Xi Xu, Di Zhang, T. Zhao, 2022, European journal of medicinal chemistry.

Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.

Qiuyu Chen, Xi Xu, Zhiyu Li, 2020, European journal of medicinal chemistry.

Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.

Yajing Wang, Jie Ren, Xi Xu, 2018, Bioorganic chemistry.

Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.

Xi Xu, Di Zhang, J. Kou, 2022, European journal of medicinal chemistry.

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer

Xi Xu, Jingwei Jiang, Wanli Ye, 2022, Acta pharmaceutica Sinica. B.

Palladium(II)-Catalyzed Reaction of Lawsones and Propargyl Carbonates: Construction of 2,3-Furanonaphthoquinones and Evaluation as Potential Indoleamine 2,3-Dioxygenase Inhibitors.

Xi Xu, Zhiyu Li, Jinlei Bian, 2018, The Journal of organic chemistry.

Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.

Xi Xu, Qianming Du, Zhiyu Li, 2020, European journal of medicinal chemistry.

Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).

R. Chen, Xi Xu, Zhiyu Li, 2022, European journal of medicinal chemistry.

Progress in the mechanism and drug development of castration-resistant prostate cancer.

Tinghan Li, Xi Xu, Zhiyu Li, 2016, Future medicinal chemistry.

Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.

C. Luo, H. Ding, Xi Xu, 2019, Journal of medicinal chemistry.

Synthesis and characterization of potential stereoisomeric and degradation impurities of ulipristal acetate

Xi Xu, Zhiyu Li, Jinlei Bian, 2019, Organic Chemistry Frontiers.

Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.

Xi Xu, Zhiyu Li, Jinlei Bian, 2018, European journal of medicinal chemistry.

Discovery and development of small molecule modulators targeting glutamine metabolism.

Xi Xu, Zhiyu Li, Jinlei Bian, 2019, European journal of medicinal chemistry.

Discovery and synthesis of novel Wogonin derivatives with potent antitumor activity in vitro.

Xi Xu, Zhiyu Li, Jinlei Bian, 2017, European journal of medicinal chemistry.

The progress and development of GLUT1 inhibitors targeting cancer energy metabolism.

Xi Xu, Zhiyu Li, Jinlei Bian, 2019, Future medicinal chemistry.

Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.

Xi Xu, Zhiyu Li, Jinlei Bian, 2018, Journal of medicinal chemistry.

Design and synthesis of indoline thiohydantoin derivatives based on enzalutamide as antiproliferative agents against prostate cancer.

Xi Xu, Zhiyu Li, Jinlei Bian, 2017, European journal of medicinal chemistry.

Discovery of novel USP8 inhibitors via Ubiquitin-Rho-110 fluorometric assay based high throughput screening.

Kaixian Chen, Hualiang Jiang, C. Luo, 2020, Bioorganic chemistry.

Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer.

Xi Xu, Qianming Du, Zhiyu Li, 2019, European journal of medicinal chemistry.

Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation

Yu Cheng, Zhiyu Li, Jie Ren, 2019, Journal of enzyme inhibition and medicinal chemistry.

Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.

Xi Xu, J. Kou, Zhiyu Li, 2021, Journal of medicinal chemistry.

Design, synthesis, and biological evaluation of novel glutaminase 1 allosteric inhibitors with an alkane chain tail group.

Xi Xu, Di Zhang, Jinlei Bian, 2023, European journal of medicinal chemistry.

Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors.

Q. You, Q. Guo, Xi Xu, 2016, Bioorganic & medicinal chemistry letters.

Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.

Q. You, Xi Xu, Zhiyu Li, 2019, Bioorganic chemistry.

Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective

Xi Xu, Jinlei Bian, Jubo Wang, 2024, Medicinal research reviews.

Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy.

Xi Xu, Jinlei Bian, Zekun Du, 2023, European journal of medicinal chemistry.

Discovery of Selenium-Containing STING Agonists as Orally Available Antitumor Agents.

Zhe Wang, Yi Ma, Xi Xu, 2022, Journal of medicinal chemistry.

Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer through Regulating ERα Expression.

H. Ding, Xi Xu, Zhiyu Li, 2022, Journal of medicinal chemistry.

Overview of the development of protein arginine methyltransferase modulators: Achievements and future directions.

Xi Xu, Jinlei Bian, Jubo Wang, 2024, European journal of medicinal chemistry.